Medicine is built on population averages. You aren’t average.

A "normal" lab range is just what's typical for a reference population. It may not mean optimal for you.

Meet DanielIllustrative example

Fit, busy, family history of Alzheimer's

Daniel is 41, a lawyer in Manhattan, and sleeps about six hours on a good night. He asked about Alzheimer's at his welcome call because his grandmother had it. His last physical came back with the line most people get: "Everything looks fine." Homocysteine and omega-3 weren't checked at all.

Daniel in a linen shirt, eyes closed, face tilted toward the light.

Daniel, 41

  • Vitamin B12380 pg/mL
  • Blood pressure126/82

Not on a typical panel

  • Homocysteine14.5 µmol/L
  • APOEε4/ε4
  • Omega-34.2%
  • Alzheimer's PRS58th pct
  • Sleep, 30-day avg6h 05m
His genome

His genome carries the strongest common genetic risk for Alzheimer's

We sequenced Daniel's whole genome and found that he carries two copies of APOE ε4. He carries roughly 14 times the risk of people with the most common genotype.1,2

ε2/ε3protective
0.6x
ε3/ε3most common
1x
ε3/ε4one copy
3.2x
ε4/ε4 · Danieltwo copies
14.5x
08x16x

Odds of Alzheimer's disease relative to the ε3/ε3 genotype

Where Daniel's APOE genotype falls against the others. Two copies of ε4 carry the highest risk of any common genotype.1 A 40-study meta-analysis put the ε4/ε4 range at 12.5 to 14.9.2

Two readings of the same number

Standard Target< 15

14.5µmol/L

Lab report flags nothing.

“Homocysteine looks fine”

Homocysteine is linked to Alzheimer's, especially for ε4 carriers

Independent of APOE carrier status, homocysteine above 14 nearly doubled the risk of Alzheimer's disease, and each 5 µmol/L higher raised it by about 40%.3 For ε4 carriers specifically, those in the highest homocysteine quartile had 51% higher odds of cognitive dysfunction than carriers in the lowest.4

14 µmol/L or belowReference
1.0 x
Above 14 · Daniel, 14.5Nearly double the risk
1.9 x
01x2x
Relative risk of Alzheimer's disease, homocysteine above 14 µmol/L versus 14 or below, adjusted for age, sex and APOE genotype (95% CI 1.2 to 3.0). Framingham Study, 1,092 adults.3

Lowering it slowed brain shrinkage in a two-year trial

Daniel's homocysteine is 14.5 and his omega-3 is 4.2%. In a two-year trial, B vitamins slowed brain atrophy by 53% in people with homocysteine above 11,5 but only when omega-3 was adequate.6

53%

slower brain atrophy over two years on B vitamins, in people whose homocysteine was above 11.5

VITACOG trial · Smith et al., PLoS One 20105

A tighter target for two copies of ε4

Given Daniel carries 2 copies of ε4, SONATA sets his homocysteine target below 8 and his omega-3 target above 5.5%, the levels where the evidence shows lower risk and where B vitamins worked.4,6

His plan

Clear next steps

Daniel's SONATA doctor walks him through the plan, explains his genetic risk and what his biomarkers mean, and prescribes what he needs.

Priority 1

B vitamins and omega-3, together

  • startB Vitamin1 capsule daily

    A daily B-vitamin to lower homocysteine.

  • startOmega-3 Fish Oil2g daily

    A higher 2g dose of omega-3, since ε4 makes it harder for DHA to reach the brain.7,8 B vitamins need adequate omega-3 to work.6

Priority 2

Sleep and exercise

  • adjustSleep7-9 hours

    Persistent six-hour sleep at 50 carries 30% higher dementia risk, and ε4 carriers who sleep well perform like non-carriers.9,10

  • adjust150 min Zone 2 TrainingWeekly

    Physically active ε4 carriers track the cognitive trajectory of active non-carriers.11

Ongoing

A care plan that evolves with him

  • At six months, he retests homocysteine, omega-3 and B12 to see whether the supplements are working.
  • His SONATA doctor may recommend a p-tau217 blood test. It measures a protein that rises years before symptoms, giving him a baseline to track and the chance to intervene early.13
The Difference

Found at 41, two decades before symptoms typically begin

With SONATA, Daniel brings homocysteine below 8, sleeps seven hours, and exercises most days. Physically active ε4 carriers showed cognitive trajectories similar to active non-carriers over 18 months, while sedentary carriers declined fastest.11

Daniel seated in a linen shirt, looking off to the side.

40%

of dementia worldwide is attributable to 12 modifiable risk factors

Livingston et al., Lancet 202012

Find out what in range means for you

Whole genome, 140+ biomarkers, pace of aging, and a care team that sets your targets from your biology.

Keep reading

See other examples

Sources

  1. Belloy ME, et al. A quarter century of APOE and Alzheimer's disease: progress to date and the path forward. Neuron. 2019;101:820–838.
  2. Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278:1349–1356.
  3. Seshadri S, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476–483.
  4. Gordon SM, et al. APOE ε4, homocysteine and cognitive dysfunction in the TUDA cohort. BMC Med. 2025.
  5. Smith AD, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial (VITACOG). PLoS One. 2010;5:e12244.
  6. Oulhaj A, et al. Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in mild cognitive impairment. J Alzheimers Dis. 2016;50:547–557.
  7. Arellanes IC, et al. Brain delivery of supplemental docosahexaenoic acid (DHA): a randomized placebo-controlled clinical trial. EBioMedicine. 2020;59:102883.
  8. Tomaszewski N, et al. APOE genotype and plasma DHA response in the ADCS DHA trial. J Alzheimers Dis. 2020;74:975–990.
  9. Sabia S, et al. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun. 2021;12:2289.
  10. Lim ASP, et al. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013;70:1544–1551.
  11. Smith JC, et al. Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. Front Aging Neurosci. 2014;6:61.
  12. Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–446.
  13. Palmqvist S, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024;332:1245–1257.

Daniel is an illustrative example built from typical member results. Targets and prescriptions on this page show how SONATA physicians may reason; your own targets are set by your doctor from your results, history, and goals. This page is not medical advice.